What Is New?
heart failure, nonischemic heart failure
HEART FAILURE
Based on preclinical results, it has been suggested that sodium–glucose co-transporter 2 inhibitor (SGLT2i) treatment may lead to a myocardial substrate switch and thus, improve cardiac energy reserve.This mechanistic cardiac magnetic resonance spectroscopy and imaging trial investigated 72 patients with symptomatic, nonischemic heart failure (36 with heart failure with reduced ejection fraction 36 with heart failure with preserved ejection fraction) and assessed measures of cardiac energy metabolism, myocardial function, and structure.Compared with placebo, treatment with the SGLT2i empagliflozin for 12 weeks did not enhance myocardial energy metabolism or serum metabolites associated with energy metabolism.